|
T6889 |
MI-136
|
|
Apoptosis
,
Epigenetic Reader Domain
,
Androgen Receptor
|
|
MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced. |
|
T6258 |
Zibotentan
|
ZD4054 |
Apoptosis
,
Endothelin Receptor
|
|
Zibotentan (ZD4054) (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3. |
|
T9246 |
JNJ-63576253
|
|
Androgen Receptor
|
|
JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). |
|
T38684 |
AKR1C3-IN-4
|
AKR1C3-IN-4 |
NADPH
|
|
AKR1C3-IN-4 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research. |
|
T36841 |
IPI-9119
|
|
Fatty Acid Synthase
|
|
IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM). |
|
T9446 |
KB-0742 dihydrochloride
|
|
CDK
|
|
KB-0742 dihydrochloride is a potent, selective and orally inhibitor of CDK9. |
|
T8933 |
JNJ-63576253 free base
|
TRC253,JNJ-63576253 |
Androgen Receptor
|
|
JNJ-63576253 free base (TRC253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the re... |
|
T28502 |
Ralaniten
|
EPI-002 |
Androgen Receptor
|
|
Ralaniten (EPI-002) is a potent, specific, and orally active antagonist of the androgen receptor N-terminal structural domain (AR-NTD).Ralaniten inhibits AR transcriptional activity with an IC50 value of 7.4 μM.Ralanites... |
|
T39954 |
AU-15330
|
|
Epigenetic Reader Domain
,
PROTACs
|
|
AU-15330 is a protein hydrolysis-targeted chimeric (PROTAC) degrader of the SWI/SNF ATPase subunits SMARCA2 and SMARCA4.AU-15330 potently inhibits tumor growth in a prostate cancer xenograft model and acts synergisticall... |
|
T76758 |
Rilotumumab
|
AMG 102 |
c-Met/HGFR
|
|
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (... |
|
T16807 |
Rucaparib monocamsylate
|
Rucaparib Camsylate |
PARP
|
|
Rucaparib monocamsylate (Rucaparib Camsylate) is a PARP inhibitor (PARP1,Ki of 1.4 nM). Rucaparib Camsylate also displays binding affinity to eight other PARP domains. |
|
T9005 |
VPC-80051 racemate
|
|
Others
|
|
VPC-80051 is the first small molecule inhibitor of hnRNP A1 splicing activity by using a computer-aided drug discovery approach. |
|
T7752 |
(S,R,S)-AHPC-Me
|
VHL ligand 2,E3 ligase Ligand 1A |
Ligand for E3 Ligase
|
|
(S,R,S)-AHPC-Me (E3 ligase Ligand 1A) (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein[1]. (S,R,S)-AHPC-Me can be used to synthesize ARV-771. ARV-771 is a... |
|
T6127 |
Rucaparib Phosphate
|
AG-014699 phosphate,PF-01367338,AG-014699,PF-01367338 phosphate |
PARP
|
|
Rucaparib Phosphate (PF-01367338 phosphate) is an inhibitor of PARP (Ki: 1.4 nM for PARP1) that is used in clinical therapy to sensitize cancer cells to chemotherapy. |
|
T4463 |
Rucaparib
|
AG-14447,PF-01367338,AG014699 |
PARP
|
|
Rucaparib (PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP. |
|
T61653 |
VPC-13789
|
|
|
|
VPC-13789 is a highly potent, selective, and orally bioavailable antiandrogen compound that shows promise for studying and developing therapeutics for castration-resistant prostate cancer (CRPC). In LNCaP cells, VPC-1378... |
|
T64289 |
Rucaparib camsylate
|
|
|
|
Rucaparib (AG014699) camsylate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki=1.4 nM for PARP-1. Rucaparib camsylate is an inhibitor of hexose hexaphosphate dehydrogenase (H6PD). Ruc... |
|
T70847 |
BMS-351
|
|
|
|
BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely t... |
|
T74094 |
5,6-Dihydroabiraterone
|
|
|
|
5,6-Dihydroabiraterone, a metabolic derivative of Abiraterone, is a potent and irreversible inhibitor of CYP17A1, exhibiting antiandrogen and antitumor activities, particularly effective against castration-resistant pros... |
|
T61657 |
Rucaparib acetate
|
|
|
|
Rucaparib (AG014699) acetate is a highly effective oral inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP1. Additionally, it exhibits inhibitory action on h... |
|
T13671L |
(S,R,S)-AHPC-Me dihydrochloride
|
VHL ligand 2 dihydrochloride,E3 ligase Ligand 1 dihydrochloride,(S,R,S)-AHPC-Me dihydrochloride (1948273-02-6 free base) |
Others
|
|
(S,R,S)-AHPC-Me dihydrochloride, also known as VHL ligand 2 dihydrochloride, is a chemical compound utilized in the synthesis of ARV-771. ARV-771, a BET PROTAC degrader relying on von Hippel-Landau (VHL) E3 ligase, demon... |
|
T63065 |
Rucaparib tartrate
|
|
|
|
Rucaparib (AG014699) tartrate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) and acts on PARP-1 (Ki: 1.4 nM).Rucaparib tartrate is a hexose hexaphosphate dehydrogenase (H6PD) inhibitor. Rucapa... |
|
T63811 |
EPI-7170
|
|
|
|
EPI-7170 is a ralaniten analogue and a potent antagonist of the androgen receptor N-terminal structural domain, blocking the transcriptional activity of the full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170... |
|
T61335 |
Rucaparib hydrochloride
|
|
|
|
Rucaparib hydrochloride, also known as AG014699, is a powerful and orally active compound that inhibits PARP proteins including PARP-1, PARP-2, and PARP-3 with a Ki value of 1.4 nM for PARP1. Additionally, Rucaparib hydr... |
